Proton Pump Inhibitors for the Treatment of Laryngopharyngeal Reflux. A Systematic Review

• Published in: Journal of voice 2020-11, Vol.34 (6), p.918-929
• Main Authors: Spantideas, Nikolaos, Drosou, Eirini, Bougea, Anastasia, AlAbdulwahed, Reem
• Format: Article
• Language: English
• Subjects: Gastroesophageal reflux; Humans; Laryngopharyngeal reflux; Laryngopharyngeal Reflux - diagnosis; Laryngopharyngeal Reflux - drug therapy; Laryngoscopy; Proton pump inhibitors; Proton Pump Inhibitors - therapeutic use; Treatment Outcome
• ISSN: 0892-1997; 1873-4588
• DOI: 10.1016/j.jvoice.2019.05.005

To give, if possible, an answer in the long-standing debate of the efficacy of proton pump inhibitors (PPIs) in treating laryngopharyngeal reflux (LPR) through published systematic reviews and meta-analyses. PubMed, Cochrane Library, and EMBASE were searched from 1984, the year the term LPR first appeared in the literature, until October 2018. Systematic reviews and meta-analyses comparing the treatment response of PPI therapy in patients with LPR were included in our study. Nine eligible studies, two systematic reviews and seven meta-analyses, were identified and analyzed in our study. Three of these were published in 2006, one in 2007, one in 2013, and four in 2016. Five studies published before 2016 and one in 2016 showed no benefit from PPI therapy for LPR patients while the three remaining meta-analyses of 2016 showed a significant improvement in LPR symptoms but no significant difference in response rate and reflux finding scores (RFS) between PPI therapy and placebo treatment. Based on the existing data, the use of PPI therapy for the treatment of LPR remains questionable. Six out of the nine systematic reviews/meta-analyses concluded that PPI therapy is not superior to placebo and three concluded that PPI therapy significantly improved LPR symptoms although they did not identify any difference in the post-treatment laryngoscopic findings. There is still a long way to go until we can give a definite answer to this question but in the meantime, the use of PPI therapy for the treatment of LPR will continue even though existing evidence is poor and weak, coming mainly from individual uncontrolled studies.